What is the difference between Semaglutide and Tirzepatide?

Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is classified as: Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide). Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction.

Is Semaglutide or Tirzepatide approved?

Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Semaglutide and Tirzepatide?

Peptide Science Daily tracks 500 registered clinical trials for Semaglutide (evidence grade A) and 277 for Tirzepatide (evidence grade A).

Compound comparison

Semaglutide vs Tirzepatide

This page sets Semaglutide and Tirzepatide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Tirzepatide
Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
Mechanism: Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
Tirzepatide
In plain terms, tirzepatide imitates two natural gut hormones that lower blood sugar and reduce appetite.
United States (FDA): Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
Tirzepatide
Approved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).
European Union (EMA): Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Tirzepatide
Authorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022).
Australia (TGA): Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
Tirzepatide
Registered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription.
WADA: Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Tirzepatide
Not prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance.
Evidence grade: Semaglutide
A
Tirzepatide
A
Tracked clinical trials: Semaglutide
500
Tirzepatide
277
Full profile: Semaglutide
Semaglutide profile
Tirzepatide
Tirzepatide profile

Comparison of Semaglutide and Tirzepatide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Semaglutide	Tirzepatide
Class	Glucagon-like peptide-1 (GLP-1) receptor agonist	Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
Mechanism	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.	In plain terms, tirzepatide imitates two natural gut hormones that lower blood sugar and reduce appetite.
United States (FDA)	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.	Approved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).
European Union (EMA)	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.	Authorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022).
Australia (TGA)	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.	Registered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription.
WADA	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.	Not prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance.
Evidence grade	A	A
Tracked clinical trials	500	277
Full profile	Semaglutide profile	Tirzepatide profile

Common questions

What is the difference between Semaglutide and Tirzepatide?: Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide is classified as: Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide). Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction.
Is Semaglutide or Tirzepatide approved?: Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Semaglutide and Tirzepatide?: Peptide Science Daily tracks 500 registered clinical trials for Semaglutide (evidence grade A) and 277 for Tirzepatide (evidence grade A).